YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Longeveron Inc. (NASDAQ:LGVN) reported on September 16 that ELPIS II, its randomized Phase 2b trial in 40 infants with hypoplastic left heart syndrome, missed its primary efficacy endpoint. The study evaluated laromestrocel as an adjunct t…
Longeveron Stephen WillardStephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN) MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life…
Earnings Call Insights: Longeveron (LGVN) Q2 2026 MANAGEMENT VIEW * "Longeveron is approaching a series of potentially transformative milestones across our 4 stem cell therapy development programs" (CEO & Director Stephen Willard), while r…
Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) entitled “Laromestrocel Stabilizes Brain Inflammation In Key Alzheimer’s Disease Gray And White Matter Regions As Assessed Using Free Water MRI” presen…
(RTTNews) - Longeveron Inc. (LGVN) on Monday announced that Chief Financial Officer Lisa Locklear is stepping down to pursue board opportunities and other professional and personal interests. The company appointed Marie Washburn as Senior…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as trial endpoint misses. In the Green - Premar…
MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the…
Earnings Call Insights: Longeveron (LGVN) Q1 2026 MANAGEMENT VIEW * “After I took on the role as CEO in February, we embarked on 2 immediate critical tasks, a comprehensive review of the company's assets, development and strategic plan and…
On Wednesday, Longeveron (NASDAQ:LGVN) discussed first-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
(RTTNews) - Longeveron Inc. (LGVN) on Friday announced it held a constructive Type C meeting with the U.S. FDA regarding its ongoing Phase 2b ELPIS II trial of laromestrocel (Lomecel-B) in hypoplastic left heart syndrome (HLHS). The FDA ac…
MIAMI, May 08, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced t…
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB: AVAI), Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Viking Therapeutics, Inc. (NASDAQ: VKTX), Longeveron Inc. (NA…
Thepatent relates to potency assay methods for assessing human mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, peripheral blood, a lung, a heart, amniotic fluid, inner organs, an amniotic membrane, an umbilical cord…
Issued on behalf of Avaí Bio, Inc. Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics (NASDAQ: FATE), Mesoblast (NASDAQ: MESO), Longeveron (NASDAQ: LGVN) Key Takeaways: • Avaí Bio…
Longeveron (LGVN) stock closed significantly higher on March 10 after the biotech firm announced a private placement generating about $30 million from institutional and accredited investors. The financing comprises an initial $15 million t…
Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms,with an impressive history of delivering significant fundraises and strategic collaborationsC…
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to female patients with sexual dysfunction in order to increase sexual quality of lifeFemale sexual dysfun…
MIAMI, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced…
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients with non-ischemic dila…
Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to placebo across multiple k…
(RTTNews) - Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle. Modular Medical, Inc. (MODD) shares surged i…
MIAMI, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its…
Thepatent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for aging-related frailty,…
MIAMI, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that i…
Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHSFull enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as…
MIAMI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that i…
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that G…
NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to announce it will host the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Metropolitan C…
Exploring potential partnerships and strategic opportunities for the Company’s stem cell therapy program in Alzheimer’s diseaseAlzheimer’s disease development program with positive data in successful Phase 1 and Phase 2a clinical trialsCle…
* Longeveron (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]) appointed Than Powell as interim chief executive officer, effective immediately. * Powell replaces Wa’el Hashad. * Company founder and chief science officer Joshua Hare was…
Than Powell, Chief Business Officer and head of business development, appointed Interim CEODr. Joshua Hare, co-founder and chief science officer, appointed Executive Chairman of the Board of DirectorsWa’el Hashad to step down as CEO and Bo…
MIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions,…
These stocks have an unusual volume in today's session [unusualvolume] TOP UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT ADD [https://www.chartmill.com/stock/quote/ADD/profile] -9.78% The trading volume of COLOR STAR TECHNOLOGY CO-A (NASDAQ:…
* Longeveron press release [https://seekingalpha.com/pr/20200156-longeveron-announces-second-quarter-2025-financial-results-and-provides-business-update] (NASDAQ:LGVN [https://seekingalpha.com/symbol/LGVN]): Q2 GAAP EPS of -$0.33 beats by…
LONGEVERON INC. (NASDAQ:LGVN [https://www.chartmill.com/stock/quote/LGVN]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, EPS NARROWER THAN EXPECTED Longeveron Inc., a clinical-stage biotechnology company focused on regenerative medic…